Structured Summary
Abstract
An anti-CTLA-4 ANTIGEN monoclonal antibody initially indicated for the treatment of certain types of metastatic MELANOMA. Its mode of actions may include blocking of CTLA-4 mediated inhibition of CYTOTOXIC T LYMPHOCYTES, allowing for more efficient destruction of target tumor cells.
MeSH Record
Classification
Broader headings
Related Concepts
Knowledge Graph
Drag nodes to rearrange; hover to trace links; click a node to open its page.
Drug Class
Pharmacological Action
MeSH Record
See Also
MeSH Record
Synonyms
9 entry terms
- Anti-CTLA-4 MAb Ipilimumab
- Anti CTLA 4 MAb Ipilimumab
- Ipilimumab, Anti-CTLA-4 MAb
- MDX 010
- MDX-010
- MDX-CTLA-4
- MDX010
- Yervoy
- MDX CTLA 4
MeSH Record
Aspects Covered
24 allowable subheadings
Indexed with the subheadings administration & dosage, adverse effects, analysis, biosynthesis, blood, cerebrospinal fluid, chemistry, classification, drug effects, economics, genetics, history, immunology, isolation & purification, metabolism, pharmacokinetics, pharmacology, physiology, poisoning, radiation effects, therapeutic use, toxicity, ultrastructure, urine.
MeSH Record
History Note
2018(2012)
MeSH Hierarchy
Tree Numbers
AMA Style
References
- National Library of Medicine. Ipilimumab. Medical Subject Headings (MeSH). 2026. Unique ID D000074324. http://id.nlm.nih.gov/mesh/2026/D000074324
- Ipilimumab. In: Wikipedia. https://en.wikipedia.org/wiki/Ipilimumab
- Ipilimumab. In: Wikidata. https://www.wikidata.org/wiki/Q2459042